Search

Your search keyword '"PNA-clamp"' showing total 2 results
Start Over Descriptor "PNA-clamp"
2 results on '"PNA-clamp"'

1. Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.

Author

Pasquale, Raffaella, Fenizia, Francesca, Esposito Abate, Riziero, Sacco, Alessandra, Esposito, Claudia, Forgione, Laura, Rachiglio, Anna Maria, Bevilacqua, Simona, Montanino, Agnese, Franco, Renato, Rocco, Gaetano, Botti, Gerardo, Denis, Marc G, Morabito, Alessandro, De Luca, Antonella, and Normanno, Nicola

Abstract

Aim: We assessed the ability of the Therascreen® kit (plasma-Therascreen) and of a peptide nucleic acids (PNA)-clamp approach to detect EGFR mutations in plasma-derived circulating-free tumor DNA (cftDNA) from non-small-cell lung cancer patients. Materials & methods: cftDNA from 96 patients was analyzed for exon 19 deletions and the p.L858R mutation, using both plasma-Therascreen and PNA-clamp-based assays. Results: None of the 70 EGFR wild-type patients showed EGFR mutations in cftDNA with both techniques (specificity: 100%). In 17/26 EGFR-mutant patients, plasma-Therascreen analysis confirmed the mutation identified in the primary tumor (analytical sensitivity: 65.4%). Similar results were obtained with the PNA-clamp method. Conclusion: Both approaches were specific and sensitive for EGFR mutational analysis of cftDNA in non-small-cell lung cancer patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

2. Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients

Author

Simona Bevilacqua, Riziero Esposito Abate, Claudia Esposito, Gaetano Rocco, Marc G. Denis, Gerardo Botti, Anna Maria Rachiglio, Agnese Montanino, Antonella De Luca, Alessandra Sacco, Raffaella Pasquale, Francesca Fenizia, Alessandro Morabito, Laura Forgione, Renato Franco, Nicola Normanno, Pasquale, Raffaella, Fenizia, Francesca, Esposito Abate, Riziero, Sacco, Alessandra, Esposito, Claudia, Forgione, Laura, Rachiglio, Anna Maria, Bevilacqua, Simona, Montanino, Agnese, Franco, Renato, Rocco, Gaetano, Botti, Gerardo, Denis, Marc G., Morabito, Alessandro, De Luca, Antonella, and Normanno, Nicola

Subjects
Male, Lung Neoplasms, DNA Mutational Analysis, Exon, Biology, medicine.disease_cause, Sensitivity and Specificity, DNA Mutational Analysi, chemistry.chemical_compound, Genetic, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Genetics, medicine, non-small-cell lung carcinomA, Humans, Liquid biopsy, Lung cancer, PNA-clamp, Aged, Sequence Deletion, Aged, 80 and over, Pharmacology, Mutation, liquid biopsy, Medicine (all), Exons, DNA, Neoplasm, Middle Aged, medicine.disease, Molecular biology, Primary tumor, ErbB Receptors, Lung Neoplasm, Therascreen®, chemistry, cftDNA, Nucleic acid, Cancer research, Molecular Medicine, Female, Receptor, Epidermal Growth Factor, EGFR mutation, DNA, Human
Abstract

Aim: We assessed the ability of the Therascreen® kit (plasma-Therascreen) and of a peptide nucleic acids (PNA)-clamp approach to detect EGFR mutations in plasma-derived circulating-free tumor DNA (cftDNA) from non-small-cell lung cancer patients. Materials & methods: cftDNA from 96 patients was analyzed for exon 19 deletions and the p.L858R mutation, using both plasma-Therascreen and PNA-clamp-based assays. Results: None of the 70 EGFR wild-type patients showed EGFR mutations in cftDNA with both techniques (specificity: 100%). In 17/26 EGFR-mutant patients, plasma-Therascreen analysis confirmed the mutation identified in the primary tumor (analytical sensitivity: 65.4%). Similar results were obtained with the PNA-clamp method. Conclusion: Both approaches were specific and sensitive for EGFR mutational analysis of cftDNA in non-small-cell lung cancer patients.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results